GSK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GSK is not a strong buy for a beginner investor with a long-term strategy at this moment. Despite strong financial performance in the latest quarter, the technical indicators suggest a bearish trend, and the lack of significant positive catalysts or strong trading signals makes it less appealing for immediate investment.
The MACD is negative and expanding, indicating a bearish trend. RSI is at 22.706, suggesting the stock is oversold but not yet signaling a reversal. Moving averages are converging, showing no clear trend. The stock is trading near support levels (S1: 55.624), with resistance at 57.66.
The company reported strong financial growth in Q4 2025, with revenue up 10.24% YoY and net income up 59.51% YoY. EPS increased by 61.54%, and gross margin improved slightly to 69.7%. Analysts have raised price targets, indicating some confidence in the company's potential.
Technical indicators suggest a bearish trend. Analysts' ratings are mostly neutral or underweight, with mid-term growth challenges highlighted. No significant hedge fund or insider trading trends. The stock's short-term price movement predictions are minimal, with a slight chance of decline in the next month.
In Q4 2025, GSK demonstrated strong financial performance with revenue growth of 10.24% YoY, net income growth of 59.51% YoY, and EPS growth of 61.54% YoY. Gross margin also improved slightly to 69.7%.
Analysts have mixed views on GSK. While some have raised price targets (e.g., TD Cowen to $70, BofA to 2,350 GBp), the majority maintain neutral or underweight ratings, citing mid-term growth challenges and loss of exclusivities. The company's acquisition of Rapt Therapeutics has also drawn mixed reactions.
